drugset / Trial / NCT01811472
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
Timeline
- Start
- 2013-06
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pradigastat | Small molecule | 10 mg | — |
| Subject | Pradigastat | Small molecule | 20 mg | — |